Abstract
Advances in genomic technologies have enabled a deeper understanding of a variety of phenotypes relevant to clinical medicine. The ability to test hundreds of thousands of inherited genetic markers for association with medical traits (genome-wide association studies, or GWAS) has led to exciting new discoveries. While GWAS of diseases focuses on disease onset and rate of progression, the term pharmacogenomics refers to the application of GWAS and related genomic technologies to understanding variability in treatment outcome of a disease (a drug's efficacy or toxicity).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
